Results 121 to 130 of about 12,593 (182)

MICA-129Met/Val as a therapeutic compass in idiopathic pulmonary fibrosis: prognosis and antifibrotic benefit. [PDF]

Front Immunol
Mocci S, Mereu C, Littera R, Deidda S, Cannas F, Lorrai M, Zedda E, Murgia M, Sanna C, Giuressi E, Lai S, Perra A, Floris M, Giglio S.   +13 more
europepmc   +1 more source

Pirfenidone treatment attenuates fibrosis in autosomal dominant polycystic kidney disease. [PDF]

JCI Insight
Remadevi V, Jamadar A, Varghese MM, Yang H, Gunewardena S, Wallace DP, Rao R.   +6 more
europepmc   +1 more source

Integrated Approaches in Drug Repositioning Highlight Ouabain and Helenalin as Potential Drug Candidates for Pulmonary Fibrosis. [PDF]

Comput Struct Biotechnol J
Al-Abdulraheem Z, Juppi HK, Morikka J, Inkala S, Perho N, Sani S, Serra A, Federico A, Fratello M, Greco D.   +9 more
europepmc   +1 more source

Hepcidin as a Biomarker of Response to Antifibrotic Therapy in Idiopathic Pulmonary Fibrosis. [PDF]

J Clin Med
Yilmaz Gunes G, Çoban H, Erel F, Akış Yılmaz M, Sarioglu N, Colak M, Yumrukuz Senel M.   +6 more
europepmc   +1 more source

Microarray chip to fabricate 3D PDAC heterospheroids with architectural organization towards tumor invasion and chemoresistance study. [PDF]

Microsyst Nanoeng
Wei X, Lan X, Pan Y, Wang L, Chen K, Xu M.   +5 more
europepmc   +1 more source

Determinants of fungal infection and hospital readmission risk in interstitial pneumonia with autoimmune features: associations with vitamin D and pirfenidone. [PDF]

Front Immunol
Yuan G, Xie X, Tang M, Zheng X, Luo X, Xiong A.   +5 more
europepmc   +1 more source

Transcriptomic signatures of IPF in ALI-cultured airway cells and their therapeutic implications. [PDF]

Thorax
Chua RL, Veith C, Schneider MA, Jechow K, Kaufhold G, Alkildani S, Wild M, Sudy A, Xu EC, Kreuter M, Boots A, Eils R, Kahn NC, Conrad C.   +13 more
europepmc   +1 more source

Real-world persistence with antifibrotic treatments: a nationwide study on claims data in France (The REPEAT study). [PDF]

Respir Res
Cottin V, Najean M, Arnee E, Voulgaridou M, Dillard C, Ansolabehere X, Doublet M, Chollet J, Leroy S, Jouneau S.   +9 more
europepmc   +1 more source

Efficacy and safety of nintedanib combined with pirfenidone versus monotherapy in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. [PDF]

Am J Transl Res
Xu S, Li L, Lu W, Liu R.
europepmc   +1 more source

Efficacy and tolerability of generic pirfenidone after switch from Esbriet^® in idiopathic pulmonary fibrosis: a real-world observational study. [PDF]

Intern Emerg Med
Tonelli R, Turchiano MG, Moretti A, Andrisani D, Gozzi F, Raineri G, Raineri G, Samarelli AV, Andolfi F, Ruggieri V, Clini E, Cerri S.   +11 more
europepmc   +1 more source